Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in patients with cancer; and BEMA Buprenorphine that is in Phase III trial for the treatment of chronic pain in a mixed opioid naïve and opioid experienced population. The company is also involved in the development of BUNAVAIL for the maintenance treatment of opioid dependence; and Clonidine Topical Gel for the treatment of painful diabetic neuropathy. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine; and license agreement with Arcion Therapeutics.
|Shares Outstanding||EPS||-0.35||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-5.98%||Sales Growth - Q/Q||412.53%||P/E||-6.57|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-70.05%||ROE||-115.89%||ROI||-109.33%|
|Current Ratio||2.42||Quick Ratio||2.34||Long Term Debt/Equity||0.05||Debt Ratio||0.59|
|Gross Margin||82.95%||Operating Margin||-150.93%||Net Profit Margin||-184.52%||Dividend Payout Ratio|
|Cash From Financing Activities||-1.86 M||Cash From Investing Activities||-140 K||Cash From Operating Activities||-5 M||Gross Profit||11.93 M|
|Net Profit||-8.19 M||Operating Profit||-7.8 M||Total Assets||82.47 M||Total Current Assets||71.74 M|
|Total Current Liabilities||29.59 M||Total Debt||10.26 M||Total Liabilities||32.62 M||Total Revenue||13.05 M|
|High 52 week||5.3||Low 52 week||1.7||Last close||4.57||Last change||-0.44%|
|RSI||36.36||Average true range||0.19||Beta||0.69||Volume||448.88 K|
|Simple moving average 20 days||-5.36%||Simple moving average 50 days||-6.96%||Simple moving average 200 days||16.74%|
|Performance Week||-7.86%||Performance Month||-2.35%||Performance Quart||-1.3%||Performance Half||26.24%|
|Performance Year||134.36%||Performance Year-to-date||23.51%||Volatility daily||1.98%||Volatility weekly||4.43%|
|Volatility monthly||9.07%||Volatility yearly||31.42%||Relative Volume||117.27%||Average Volume||1.09 M|
|New High||New Low|
2020-05-26 10:43:17 | Baker Brothers Snap Up These 3 Small-Cap Biotech Stocks
2020-05-11 08:30:10 | BioDelivery Sciences Appoints Jeff Bailey Interim CEO
2020-05-09 17:01:26 | Biodelivery Sciences International Inc BDSI Q1 2020 Earnings Call Transcript
2020-05-08 18:22:29 | Edited Transcript of BDSI earnings conference call or presentation 7-May-20 8:30pm GMT
2020-05-08 10:52:02 | BioDelivery BDSI Beats on Q1 Earnings, Withdraws Guidance
2020-05-07 18:35:10 | BioDelivery Sciences International BDSI Beats Q1 Earnings and Revenue Estimates
2020-05-07 16:01:10 | BioDelivery Sciences Reports Strong Q1 2020 Results
2020-04-30 12:34:04 | BioDelivery Sciences International BDSI Earnings Expected to Grow: Should You Buy?
2020-04-28 08:00:10 | BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020
2020-04-27 12:31:04 | BioDelivery Sciences International BDSI Earnings Expected to Grow: Should You Buy?
2020-03-14 08:51:35 | Does BioDelivery Sciences International NASDAQ:BDSI Have A Healthy Balance Sheet?
2020-03-13 09:29:01 | BioDelivery BDSI Q4 Earnings and Revenues Beat Estimates
2020-03-13 01:15:48 | Edited Transcript of BDSI earnings conference call or presentation 12-Mar-20 8:30pm GMT
2020-03-12 20:55:12 | BioDelivery Sciences International BDSI Tops Q4 Earnings and Revenue Estimates
2020-03-12 16:01:10 | BioDelivery Sciences Reports Strong Fourth Quarter and Full-Year 2019 Results
2020-03-12 14:30:00 | BioDelivery Sciences International, Inc. to Host Earnings Call
2020-03-09 08:00:10 | BioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of Directors
2020-03-05 12:30:05 | BioDelivery Sciences International BDSI Earnings Expected to Grow: Should You Buy?
2020-02-06 10:44:03 | Emmaus EMMA to Report Q4 Earnings: What's in the Cards?
2020-01-30 10:15:03 | Alexion ALXN Q4 Earnings Beat Estimates, Revenues Up Y/Y
2020-01-29 10:06:03 | Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation
2020-01-27 17:20:10 | Here's Why You Should Add BioDelivery Stock to Your Portfolio
2020-01-27 10:25:03 | Will Soliris, Ultomiris Drive Alexion's ALXN Q4 Earnings?
2020-01-08 12:00:05 | What Makes BioDelivery BDSI a New Buy Stock
2019-12-30 09:44:02 | Flexion's FLXN Stock Up on FDA Approval for Zilretta sNDA
2019-12-27 19:53:00 | Argo Group, Tivity Health, Horizon Global, and Other 13D Filings
2019-12-19 08:30:10 | BioDelivery Sciences Added to NASDAQ Biotechnology Index
2019-12-12 11:30:04 | BioDelivery BDSI Up 6% Since Last Earnings Report: Can It Continue?
2019-12-10 10:48:39 | Did Hedge Funds Drop The Ball On BioDelivery Sciences International, Inc. BDSI ?
2019-12-06 12:00:05 | What Makes BioDelivery Sciences International BDSI a Strong Momentum Stock: Buy Now?
2019-12-05 09:07:02 | Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon
2019-12-03 09:16:02 | Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU
2019-12-03 08:57:01 | 5 Affordable Breakout Stocks for Stunning Returns
2019-11-29 09:13:02 | BioDelivery's Belbuca Sales & Symproic Addition Encouraging
2019-11-27 08:30:10 | BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-20 10:00:03 | What Makes BioDelivery Sciences International BDSI a Strong Momentum Stock: Buy Now?
2019-11-19 09:26:02 | Protalix Finalizes Accelerated Approval Pathway for PRX-102
2019-11-14 10:20:03 | BioDelivery BDSI Stock Up on Q3 Earnings Beat & Raised View
2019-11-13 14:48:40 | Edited Transcript of BDSI earnings conference call or presentation 12-Nov-19 9:30pm GMT
2019-11-13 08:00:01 | IVERIC bio ISEE Q3 Loss Narrows Y/Y, Zimura Advancing Well
2019-11-13 07:49:12 | 5 Breakout Stocks for Explosive Returns